RT Journal Article
T1 Frailty is an independent prognostic marker in elderly patients with myocardial infarction.
A1 Alonso Salinas, Gonzalo Luis
A1 Sanmartin, Marcelo
A1 Pascual Izco, Marina
A1 Rincon, Luis Miguel
A1 Pastor Pueyo, Pablo
A1 Marco Del Castillo, Alvaro
A1 Garcia Guerrero, Alberto
A1 Caravaca Perez, Pedro
A1 Recio-Mayoral, Alejandro
A1 Camino, Asuncion
A1 Jimenez-Mena, Manuel
A1 Zamorano, José Luis
K1 Acute Coronary Syndrome
K1 Acute Myocardial Infarction
K1 Aging
K1 Frailty
K1 Prognosis
AB Acute coronary syndrome (ACS) patients are increasingly older. Conventional prognostic scales include chronological age but do not consider vulnerability. In elderly patients, a frail phenotype represents a better reflection of biological age. This study aims to determine the prevalence of frailty and its influence on patients age ≥75 years with ACS. Patients age ≥75 years admitted due to type 1 myocardial infarction were included in 2 tertiary hospitals, and clinical data were collected prospectively. Frailty was defined at admission using the previously validated Survey of Health Ageing and Retirement in Europe Frailty Index (SHARE-FI) tool. The primary endpoint was the combination of death or nonfatal myocardial reinfarction during a follow-up of 6 months. Major bleeding (hemoglobin decrease ≥3 g/dL or transfusion needed) and readmission rates were also explored. A total of 234 consecutive patients were included. Frail patients (40.2%) had a higher-risk profile, based on higher age and comorbidities. On multivariate analysis, frailty was an independent predictor of the combination of death or nonfatal myocardial reinfarction (adjusted hazard ratio [aHR]: 2.54, 95% confidence interval [CI]: 1.12-5.79), an independent predictor of the combination of death, nonfatal myocardial reinfarction, or major bleeding (aHR: 2.14, 95% CI: 1.13-4.04), and an independent predictor of readmission (aHR: 1.80, 95% CI: 1.00-3.22). Frailty phenotype at admission is common among elderly patients with ACS and is an independent predictor for severe adverse events. It should be considered in future risk-stratification models.
YR 2017
FD 2017-07-16
LK http://hdl.handle.net/10668/11411
UL http://hdl.handle.net/10668/11411
LA en
DS RISalud
RD Apr 15, 2025